research use only

Desmopressin Acetate

Cat.No.P1084

Desmopressin is a synthetic octapeptide, and an analogue of human hormone arginine vasopressin with antidiuretic and coagulant activities. It is a selective agonist for the vasopressin V2 receptor (V2R).

Amino-acid Sequence

Desmopressin Acetate Amino-acid Sequence

CAS No. 62288-83-9

Quality Control

Batch: Purity: 99.02%
99.02

Chemical Information & Solubility

Storage (From the date of receipt) 3 years-20°C powder

In vitro
Batch:

DMSO : 100 mg/mL (88.55 mM);
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Biological Activity

Description Desmopressin is a synthetic octapeptide, and an analogue of human hormone arginine vasopressin with antidiuretic and coagulant activities. It is a selective agonist for the vasopressin V2 receptor (V2R).

In vitro

In vitro Desmopressin (DDAVP) is a selective agonist for the vasopressin V2 receptor (V2R), which is coupled to cAMP-dependent signaling. DDAVP induces cAMP-dependent eNOS activation via Ser1177 phosphorylation. DDAVP (at doses ranging from 100 ng/ml to 1 μg/ml) exerts a modest but significant antiproliferative effect on cultured CT-26 and Colo-205 cells.
Cell Research Cell lines HUVECs
Concentrations 1 μM
Incubation Time 25 min
Method

HUVECs are transduced with recombinant adenoviruses AdV2R.EGFP (AdV2R) or AdlacZ. 3 days later cells are incubated for 25 min with 1 μM DDAVP or 10 μM forskolin, both in presence of IBMX. Cell extracts are analyzed for eNOS Ser1177 phosphorylation and eNOS expression.

In Vivo

In vivo In vivo, DDAVP (2 μg/kg) reduces accumulation of ascites and formation of intestinal tumor nodules in mice intraperitoneally inoculated with CT-26 cells. Perioperative administration of DDAVP significantly inhibits tumor progression in animals surgically implanted in the spleen with CT-26 cells, and causes some reduction in liver metastasis. DDAVP is able to inhibit lung colonization by blood-borne breast cancer cells in an experimental murine model. It dramatically reduces lymph node and lung metastasis in a model of mammary tumor manipulation and surgical excision in mice when administered perioperatively, and also exerts antitumor effects in combination with chemotherapy. DDAVP increases the plasma levels of coagulation factor VIII, von Willebrand factor (VWF) and tissue-type plasminogen activator, and also enhances platelet adhesion to the vessel wall.
Animal Research Animal Models Syngeneic adult male Balb/c mice inoculated intraperitoneally or intrasplenically with CT-26 colon cancer cells
Dosages 2 μg/kg body weight
Administration i.v.

References

  • https://pubmed.ncbi.nlm.nih.gov/12871421/
  • https://pubmed.ncbi.nlm.nih.gov/12871421/

Product Information

Molecular Formula

C46H64N14O12S2.C2H4O2

Molecular Weight 1129.27
CAS No. 62288-83-9
Appearance White Powder
Peptide Content (by %N) ≥80%
Single Impurity (by HPLC) ≤1.0%
Assay (By Anhydrous, Acetic Acid-free) 95.0~105.0%
MS Consistent
Packing plastic vial(dedicated for peptide packing) or glass vial, quantity according to customer's detail requirement.
Storage
(From the date of receipt)
3 years-20°C powder
Shipping Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)